Incannex Healthcare Inc. announced the commencement of patient dosing in its DReAMzz Phase 2 dose-optimization study for IHL-42X, a combination therapy for obstructive sleep apnea. The U.S. Patent and Trademark Office granted a composition patent for IHL-42X with an expiry date of July 9, 2040. As of August 31, 2026, the company reported approximately $70 million in cash and no debt, bolstered by over A$11.2 million in non-dilutive capital received during 2026. Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications.

Incannex Healthcare Inc. announced the dosing of the first patient in its DReAMzz Phase 2 dose-optimization study for IHL-42X, an oral fixed-dose combination drug candidate for obstructive sleep apnea. This milestone follows positive results from the prior Phase 2 RePOSA study, which demonstrated statistically significant reductions in the apnea-hypopnea index (AHI) of up to 83% and established a strong safety profile. The company also highlighted its FDA Fast Track designation for IHL-42X, which facilitates expedited review due to unmet medical needs. The DReAMzz study involves 14 clinical sites in the United States and aims to optimize dosing to support future Phase 3 development. Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications including obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.

Incannex Healthcare Inc. received a final A$5,102,788.30 refund under the Australian Government’s Research and Development Tax Incentive Program on August 11, 2026. This payment completes more than A$11.2 million in non-dilutive capital received during 2026, following a previous refund of A$6,039,162.43. The funds result from the approval of overseas findings and an amended FY25 income tax return. This receipt strengthens the company's debt-free balance sheet and financial flexibility to advance its clinical pipeline without shareholder dilution. Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies and psychedelic-assisted treatments for conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.

On July 23, 2026, Incannex Healthcare Inc. announced the commencement of participant screening for its DReAMzz Phase 2 dose confirmation study of IHL-42X, a therapy for obstructive sleep apnea (OSA). The study aims to optimize dosing and evaluate objective sleep metrics and patient-reported outcomes to support future Phase III development and regulatory approval. IHL-42X has previously received FDA Fast Track designation and showed up to an 83% reduction in the Apnea-Hypopnea Index (AHI) in prior Phase 2 data. The company has appointed a global CRO and completed drug product manufacturing to support the trial. Incannex is a clinical-stage biopharmaceutical company developing innovative therapies for high-impact medical indications.